ArticleCommunications biology2026
KLP-6 is a kinesin superfamily protein resistant to ADP inhibition.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLP-6 is a kinesin superfamily protein resistant to ADP inhibition.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Product inhibition is a common regulatory feature of ATPases, in which the hydrolysis product suppresses further enzymatic activity. Kinesins are microtubule-dependent ATPases that typically undergo inhibition by ADP, the product of ATP hydrolysis. Here, we show that the Caenorhabditis elegans kinesin-3 KLP-6 is unusually resistant to product inhibition by ADP and continues to move along microtubules at an unreduced speed even in the presence of high ADP concentrations. Kinetic measurements of the Michaelis constant for Mg·ATP (K
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.